WebJan 22, 2024 · Analyses will define if ctDNA could be detected during L2. For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be … WebMay 15, 2024 · Abstract. Purpose: ERBB2 (HER2) amplification is an emerging biomarker in colon cancer, conferring sensitivity to combination anti-HER2 therapy. Measurement of …
Abstract CT155: Long term results and ctDNA correlatives for …
WebHuman epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC, yet proper biomarkers for response/resistance prediction remain unveiled. Methods: … WebCirculating tumor DNA (ctDNA) mutations were evaluated and compared among hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) subgroups. Results: The baseline gene mutation pattern (at the time of recruitment) varied among HR/HER2 subtypes. BRCA1 and MED12 were frequently mutated in triple negative breast cancer … t side story
Efficacy and Safety Comparison of Niraparib to Placebo in …
WebJul 15, 2024 · After multiline traditional pathological HR/HER2 subtype-guided therapies, ctDNA testing could identify druggable ctDNA alterations to guide late-line therapy for patients with metastatic breast cancer. Funding. This work was supported by Key Grants of Research and Development in Hunan Province (2024SK2124, 2024SK2120), Natural … WebFeb 1, 2024 · Time to rising ctDNA defined as time to first ctDNA increase compared to baseline [ Time Frame: Treatment phase (up to five years) ] To evaluate the efficacy -in terms of time to rising ctDNA during the study follow-up- of the different arms. WebJul 6, 2024 · HER2-positive patients were in a primary cohort where 125 patients were randomised to receive trastuzumab deruxtecan and 55 patients served as controls; patients with HER2-low disease were included in a single-arm exploratory cohort for trastuzumab deruxtecan treatment. ... Regarding the liquid-based analysis of ctDNA among patients … tside university